Results 171 to 180 of about 33,041 (261)

Reply to “Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence”

Annals of Neurology, Volume 99, Issue 6, Page 1614-1615, June 2026.
Gabriel Cerono, Bruce A. C. Cree, Stephen L. Hauser, Sergio E. Baranzini   +3 more
wiley   +1 more source

Cytogenetic and Molecular Analysis of a “Double‐Hit” RUNX1 Including a RUNX1 p.Trp279* and a Cryptic Novel t(6;21)(q25;q22)/RUNX1::ARID1B in Acute Myeloid Leukemia

Genes, Chromosomes and Cancer, Volume 65, Issue 6, June 2026.
ABSTRACT Introduction Alterations involving RUNX1 are recurrent in hematologic malignancies and contribute to disease pathogenesis via dysregulation of transcriptional factors essential for hematopoiesis. Here, we report an acquired alteration in both alleles of RUNX1; one is a truncating mutation and the second is a novel RUNX1::ARID1B identified in ...
Rolando García, Jing Xu, Lan Yu, Kalayarasan Srinivasan, Sharon Koorse Germans, Olga Weinberg, Franklin Fuda, Weina Chen, Prasad Koduru   +8 more
wiley   +1 more source

Harnessing the power of natural killer cells in Lymphoma immunotherapy: Overcoming challenges and enhancing treatment options. [PDF]

Hematol Transfus Cell Ther
Roshandel E, Lasemi MV, Mehravar M, Salimi M, Majidi M, Mohammadali F, Seraji HR, Hajifathali A.   +7 more
europepmc   +1 more source

Lymph node microenvironment remodeling unlocks local antibody-mediated B cell depletion. [PDF]

Sci Adv
Garcia Z, Bardou M, Loap A, Feldmann LC, Godon O, Guerin MV, Lemaître F, Macdonald LE, Bruhns P, Serafini N, Bousso P, Grandjean CL.   +11 more
europepmc   +1 more source

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract Previous editions of the European guidelines for the management of chronic lymphocytic leukemia (CLL) were developed by experts in CLL under the auspices of the European Society for Medical Oncology (ESMO). These previous editions have served as a reference text for many physicians caring for patients with CLL.
Barbara Eichhorst, Paolo Ghia, Francesc Bosch, Ruth Clifford, Michael Gregor, Romain Guieze, Arnon P. Kater, Carsten U. Niemann, Sarka Pospisilova, Tadeusz Robak, Anna Schuh, Kostas Stamatopoulos, Tamar Tadmor, Nick York   +13 more
wiley   +1 more source

Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma. [PDF]

Cells
Maher N, Al Deeban B, Diop NM, Assaf J, Moia R, Mouhssine S, Gaidano G.   +6 more
europepmc   +1 more source

European Recommendations for Transitioning the Care of Patients With Multiple Myeloma Treated With B‐Cell Maturation Antigen Bispecific Antibodies From Academic Hospitals to Community‐Based Centers and for Outpatient Step‐Up Dosing

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction Safe outpatient delivery of B‐cell maturation antigen–targeting bispecific antibodies (BCMA‐BsAbs) in multiple myeloma (MM) is challenging, particularly during step‐up dosing (SUD). Standardized guidance for European community practice is limited.
María‐Victoria Mateos, Elena Zamagni, Massimo Gentile, Rachel Hall, Florence Lachenal, Mónica López Riñon, Rakesh Popat, Christof Scheid, Thomas Wolff, Isabel Perez‐Cruz, Mohamad Mohty   +10 more
wiley   +1 more source

CD20⁺FCRL4⁺ B Cells Activate CD8⁺ T Cells via MHC-I Restriction in Nasopharyngeal Carcinoma Anti-Tumor Immunity. [PDF]

Adv Sci (Weinh)
Zhang B, Yuan X, Gao K, You B, Wang Y, Meng L, Chen Z, Xie S, Liu Y, Dong Z, Xie S, Fan R, Wang F, Zhang J, Xie Z, Mo Y, Zhang H, Jiang W.   +17 more
europepmc   +1 more source

Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma: Real‐World Outcomes, Late Relapse Patterns, and Clinical Utility in the Chimeric Antigen Receptor T‐Cell Era

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Background Allogeneic hematopoietic cell transplantation (alloHCT) remains a curative option for relapsed or refractory (r/r) mantle cell lymphoma (MCL), although its role has shifted in the era of Bruton tyrosine kinase inhibition (BTKi) and chimeric antigen receptor T‐cell (CAR‐T) therapy.
Enver Aydilek, Paolo Mazzeo, Justin Hasenkamp, Markus Maulhardt, Tobias Tix, Evgenii Shumilov, Gerald Wulf   +6 more
wiley   +1 more source

B Cell Subsets and Atherosclerosis: Updates and Emerging Concepts. [PDF]

Immunol Rev
Lems S, Mazzei MG, Foks AC, McNamara CA.
europepmc   +1 more source